TEPEZZA® (teprotumumab-trbw) Dosing Information

The importance of completing full treatment course

8 IV Infusions

1 given every 3 weeks¹

Infusion 1: 10 mg/kg – 90 min¹
Infusion 2: 20 mg/kg – 90 min
Infusions 3-8: 20 mg/kg – 60 min^*
TEPEZZA dosing is based on the patient’s actual weight

^*If not well tolerated, the minimum infusion duration should remain at 90 minutes.

Find your patient’s dose

The below charts are intended to provide dosing calculations for each infusion stage for patients ranging from 40 kg to 182 kg. The dosing values can also be downloaded as a PDF.

Dosing Calculations

Determine the dosing and infusion values for your patient¹

Patients weighing 88 lbs to 168 lbs / 40 kg to 76 kg

Patient Weight		Infusion 1 (10 mg/kg)			Infusions 2 to 8 (20 mg/kg)
lb^*	kg^*	Dose (mg)	Vials required (#)	Volume to withdraw (mL)^†	Dose (mg)	Vials required (#)	Volume to withdraw (mL)^†
88	40	400	1	8.0	800	2	16.8
90	41	410	1	8.6	820	2	17.2
93	42	420	1	8.8	840	2	17.6
95	43	430	1	9.0	860	2	18.1
97	44	440	1	9.2	880	2	18.5
99	45	450	1	9.5	900	2	18.9
101	46	460	1	9.7	920	2	19.3
104	47	470	1	9.9	940	2	19.7
106	48	480	1	10.1	960	2	20.2
108	49	490	1	10.4	980	2	20.6
110	50	500	1	10.6	1000	2	21.0
112	51	510	2	10.7	1020	3	21.4
115	52	520	2	10.9	1040	3	21.8
117	53	530	2	11.1	1060	3	22.3
119	54	540	2	11.3	1080	3	22.7
121	55	550	2	11.6	1100	3	23.1
123	56	560	2	11.8	1120	3	23.5
126	57	570	2	12.0	1140	3	23.9
128	58	580	2	12.2	1160	3	24.4
130	59	590	2	12.4	1180	3	24.8
132	60	600	2	12.6	1200	3	25.2
135	61	610	2	12.9	1220	3	25.6
137	62	620	2	13.1	1240	3	26.1
139	63	630	2	13.2	1260	3	26.5
141	64	640	2	13.4	1280	3	26.9
143	65	650	2	13.7	1300	3	27.3
146	66	660	2	13.9	1320	3	27.7
148	67	670	2	14.1	1340	3	28.1
150	68	680	2	14.3	1360	3	28.6
152	69	690	2	14.5	1380	3	29.0
154	70	700	2	14.7	1400	3	29.4
157	71	710	2	14.9	1420	3	29.8
159	72	720	2	15.2	1440	3	30.2
161	73	730	2	15.3	1460	3	30.7
163	74	740	2	15.5	1480	3	31.1
165	75	750	2	15.7	1500	3	31.5
168	76	760	2	15.9	1520	3	31.9

Patients weighing 170 lbs to 247 lbs / 77 kg to 112 kg

Patient Weight		Infusion 1 (10 mg/kg)			Infusions 2 to 8 (20 mg/kg)
lb^*	kg^*	Dose (mg)	Vials required(#)	Volume to withdraw (mL)^†	Dose (mg)	Vials required(#)	Volume to withdraw (mL)^†
170	77	770	2	16.2	1540	4	32.4
172	78	780	2	16.4	1560	4	32.8
174	79	790	2	16.6	1580	4	33.2
176	80	800	2	16.8	1600	4	33.6
179	81	810	2	17.0	1620	4	34.0
181	82	820	2	17.2	1640	4	34.5
183	83	830	2	17.4	1660	4	34.9
185	84	840	2	17.6	1680	4	35.3
187	85	850	2	17.9	1700	4	35.7
190	86	860	2	18.1	1720	4	36.1
192	87	870	2	18.3	1740	4	36.6
194	88	880	2	18.5	1760	4	37.0
196	89	890	2	18.7	1780	4	37.4
198	90	900	2	18.9	1800	4	37.8
201	91	910	2	19.1	1820	4	38.2
203	92	920	2	19.3	1840	4	38.7
205	93	930	2	19.5	1860	4	39.1
207	94	940	2	19.7	1880	4	39.5
209	95	950	2	20.0	1900	4	39.9
212	96	960	2	20.2	1920	4	40.3
214	97	970	2	20.4	1940	4	40.8
216	98	980	2	20.6	1960	4	41.2
218	99	990	2	20.8	1980	4	41.6
221	100	1000	2	21.0	2000	4	42.0
223	101	1010	3	21.2	2020	5	42.4
225	102	1020	3	21.4	2040	5	42.9
227	103	1030	3	21.6	2060	5	43.3
229	104	1040	3	21.8	2080	5	43.7
232	105	1050	3	22.1	2100	5	44.1
234	106	1060	3	22.3	2120	5	44.5
236	107	1070	3	22.5	2140	5	45.0
238	108	1080	3	22.7	2160	5	45.4
240	109	1090	3	22.9	2180	5	45.8
243	110	1100	3	23.1	2200	5	46.2
245	111	1110	3	23.3	2220	5	46.6
247	112	1120	3	23.5	2240	5	47.1

Patients weighing 249 lbs to 326 lbs / 113 kg to 148 kg

Patient Weight		Infusion 1 (10 mg/kg)			Infusions 2 to 8 (20 mg/kg)
lb^*	kg^*	Dose (mg)	Vials required (#)	Volume to withdraw (mL)^†	Dose (mg)	Vials required (#)	Volume to withdraw (mL)^†
249	113	1130	3	23.7	2260	5	47.5
251	114	1140	3	23.9	2280	5	47.9
254	115	1150	3	24.2	2300	5	48.3
256	116	1160	3	24.4	2320	5	48.7
258	117	1170	3	24.6	2340	5	49.2
260	118	1180	3	24.8	2360	5	49.6
262	119	1190	3	25.0	2380	5	50.0
265	120	1200	3	25.2	2400	5	50.4
267	121	1210	3	25.4	2420	5	50.8
269	122	1220	3	25.6	2440	5	51.3
271	123	1230	3	25.8	2460	5	51.7
273	124	1240	3	26.1	2480	5	52.1
276	125	1250	3	26.3	2500	5	52.5
278	126	1260	3	26.5	2520	6	52.9
280	127	1270	3	26.7	2540	6	53.4
282	128	1280	3	26.9	2560	6	53.8
284	129	1290	3	27.1	2580	6	54.2
287	130	1300	3	27.3	2600	6	54.6
289	131	1310	3	27.5	2620	6	55.0
291	132	1320	3	27.7	2640	6	55.5
293	133	1330	3	27.9	2660	6	55.9
295	134	1340	3	28.2	2680	6	56.3
298	135	1350	3	28.4	2700	6	56.7
300	136	1360	3	28.6	2720	6	57.1
302	137	1370	3	28.8	2740	6	57.6
304	138	1380	3	29.0	2760	6	58.0
306	139	1390	3	29.2	2780	6	58.4
309	140	1400	3	29.4	2800	6	58.8
311	141	1410	3	29.6	2820	6	59.2
313	142	1420	3	29.8	2840	6	59.7
315	143	1430	3	30.0	2860	6	60.1
318	144	1440	3	30.3	2880	6	60.5
320	145	1450	3	30.5	2900	6	60.9
322	146	1460	3	30.7	2920	6	61.3
324	147	1470	3	30.9	2940	6	61.8
326	148	1480	3	31.1	2960	6	62.2

Patients weighing 329 lbs to 401 lbs / 149 kg to 182 kg

Patient Weight		Infusion 1 (1.0 mg/kg)			Infusions 2 to 8 (20 mg/kg)
lb^*	kg^*	Dose (mg)	Vials required(#)	Volume to withdraw (mL)^†	Dose (mg)	Vials required(#)	Volume to withdraw (mL)^†
329	145	1490	3	31.1	2960	6	62.6
331	150	1500	3	31.5	3000	6	63.0
333	151	1510	4	31.7	3020	7	63.4
335	152	1520	4	31.9	3040	7	63.9
337	153	1530	4	32.1	3060	7	64.3
340	154	1540	4	32.4	3080	7	64.7
342	155	1550	4	32.6	3100	7	65.1
344	156	1560	4	32.8	3120	7	65.5
346	157	1570	4	33.0	3140	7	66.0
348	158	1580	4	33.2	3160	7	66.4
351	159	1590	4	33.4	3180	7	66.8
353	160	1600	4	33.6	3200	7	67.2
355	161	1610	4	33.8	3220	7	67.6
357	162	1620	4	34.0	3240	7	68.1
359	163	1630	4	34.2	3260	7	68.5
362	164	1640	4	34.5	3280	7	68.9
364	165	1650	4	34.7	3300	7	69.3
366	166	1660	4	34.9	3320	7	69.7
368	167	1670	4	35.1	3340	7	70.2
370	168	1680	4	35.3	3360	7	70.6
373	169	1690	4	35.5	3380	7	71.0
375	170	1700	4	35.7	3400	7	71.4
377	171	1710	4	35.9	3420	7	71.8
379	172	1720	4	36.1	3440	7	72.3
381	173	1730	4	36.3	3460	7	72.7
384	174	1740	4	36.6	3480	7	73.1
386	175	1750	4	36.8	3500	7	73.5
388	176	1760	4	37.0	3520	8	73.9
390	177	1770	4	37.2	3540	8	74.4
392	178	1780	4	37.4	3560	8	74.8
395	179	1790	4	37.6	3580	8	75.2
397	180	1800	4	37.8	3600	8	75.6
399	181	1810	4	38.0	3620	8	76.1
401	182	1820	4	38.2	3640	8	76.5

^*Rounded to the nearest whole number.

^†Rounded to the nearest tenth.

DOWNLOAD
ALL DOSING INFORMATION

Please see Dosage and Administration in the TEPEZZA Prescribing Information (pdf).

In the Phase 3 study, improvement of proptosis as measured by mean change from baseline was observed as early as 6 weeks and continued to improve through Week 24.¹

Nearly

OUT
OF

patients with TED would
prefer IV medicine before
trying eye surgery⁴

Based on a survey of 102 TED patients.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of inflammatory bowel disease (IBD). IBD has been reported in some patients without a prior diagnosis of IBD. Monitor patients for signs and symptoms of IBD. If IBD exacerbation is suspected, discontinue use of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.

Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients’ hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, ear discomfort, weight decreased, nail disorders, and menstrual disorders.

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

Please see Full Prescribing Information for more information.

REFERENCES:

1. TEPEZZA (teprotumumab-trbw) [prescribing information] Amgen. 2. Ugradar S, Wang Y, Mester T, et al. Teprotumumab for thyroid eye disease: early response is not required for benefit. Eye (Lond). 2022;36(7):1403-1408. 3. Supplement to: Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341-352. 4. Data on File. Amgen, January 2023.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions

You are now leaving the site

TEPEZZA Dosing Information

8 IV Infusions

Find your patient’s dose

Dosing Calculations

Saline bag size:

In a post hoc analysis, 63% (n=15/24) of TEPEZZA patients who showed no proptosis improvement midway (12 weeks) through treatment ultimately did have a proptosis response after completing 8 infusions at 24 weeks from baseline.2

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

INDICATION

IMPORTANT SAFETY INFORMATION

In a post hoc analysis, 63% (n=15/24) of TEPEZZA patients who showed no proptosis improvement midway (12 weeks) through treatment ultimately did have a proptosis response after completing 8 infusions at 24 weeks from baseline.²